25 results
Thumbnail

D1.422 - Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals

Thumbnail

D1.425 - Impact of Early Postnatal Administration of Escherichia coli O83:K24:H31 on Immune System Maturation and Gut Barrier Function

Thumbnail

D1.429 - The major birch pollen allergen activates the NLRP3 inflammasome in THP1-ASC-GFP reporter cells

Thumbnail

D1.423 - Immunological mechanisms underlying pulmonary manifestations in pediatric long COVID patients

Thumbnail

D1.424 - Single-cell transcriptomic profiling of allergen-restimulated PBMCs reveals innate immune activation in equine insect bite hypersensitivity

Thumbnail

D1.427 - Exploring the role of lipids on initiation of allergenic response in innate lymphoid cells

Thumbnail

D1.428 - Immunomodulation of human PBMCs by peptide amphiphiles

Thumbnail

D1.430 - Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses

Thumbnail

D1.431 - Distinct Immunophenotypic Signatures in Pediatric Allergic Disease: Clinical Utility of Methylation qPCR–Based Epigenetic TBNK Profiling

Thumbnail

D1.432 - Association Between Autoimmunity and Endocrinopathy in Patients with Common Variable Immunodeficiency

Thumbnail

D1.433 - DNA Ligase I Deficiency Masquerading as CVID-Like Phenotype: Implications for Long-Term Surveillance

Thumbnail

D1.434 - Phenotyping Common Variable Immunodeficiency by Immune Dysregulation at Diagnosis: A Descriptive Comparison of Baseline Clinical and Laboratory Findings

Thumbnail

D1.435 - A TSLP Tuft Cell-Treg Cell Circuit promotes Food Allergy

Thumbnail

D1.436 - Transfusion-Related Acute Lung Injury (TRALI) following plasma transfusion: A case report

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis